Biotech News
Related news
Arbutus
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...
Recent company news
ABUSArbutus2026-10-22 11:30 EST
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
ABUSArbutus2026-10-01 11:30 EST
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-09-30 11:30 EST
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
ABUSArbutus2026-08-24 11:30 EST
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
ABUSArbutus2026-08-21 11:30 EST
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Stock data
- Close
- 4.21 USD
- Market cap
- 841.51M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States